Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Breast cancer cases in men only account for 1% of all breast cancer diagnoses. But, knowing the signs, causes, and treatments ...

Do advertisers get the attention they paid for when the big game is a blowout, like Sunday's Super Bowl LIX? Paying $8 ...

Fox sold out of its inventory of in-game spots by early November, with a 30-second commercial reportedly going for $7 million, according to Adweek. The showdown takes place Feb. 9.

Today, a brief rundown of news involving Amgen and Regeneron, as well as updates from Valneva, Turnstone Biologics and AdvanCell that you might have missed. A growing cohort of biotechs, from Biohaven ...

With major drugs like Entresto, Promacta, and Tasigna facing generic competition in 2025, Novartis could experience a substantial erosion of its revenue base. These products have been important ...